(Q38106998)

29 August 2017

title

Emerging anti-inflammatory drugs for atherosclerosis (English)

1 reference

29 August 2017

1 reference

Jeremy P Berman

1

1 reference

29 August 2017

Michael E Farkouh

series ordinal

2

1 reference

29 August 2017

Robert S Rosenson

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

16 May 2013

1 reference

Expert Opinion on Emerging Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

18

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

193-205

1 reference

Inflammation in atherosclerosis: from pathophysiology to practice

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Vascular biomarkers and surrogates in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Intensive statin therapy--a sea change in cardiovascular prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Anti-inflammatory therapeutics for the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Anti-inflammatory properties of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Pleiotropic effects of statins. - Basic research and clinical perspectives -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Phospholipase A2 enzymes and the risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Functional assessment of HDL: Moving beyond static measures for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Biology of secretory phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Association between 5-lipoxygenase expression and plaque instability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Monocyte chemoattractant protein-1 in human atheromatous plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Chemokines in atherosclerosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

Targeting adhesion molecules in cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.801453

10.1517/14728214.2013.801453

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference